What Akebia Therapeutics (AKBA) Said on Its Q3 Earnings Call
Akebia Therapeutics (AKBA) reported Q3 revenue of $36.9M, down from $58.8M YoY, with a net loss of $14.4M. The company expects Vafseo therapy costs to range between $1,000-$1,500 annually post-TDAPA. AKBA is negotiating contracts and aims for Vafseo to become a standard of care, potentially treating 200,000-250,000 patients. Clinical trials showed Vafseo's active ingredient, vadadustat, reduced hospitalizations by 10% compared to ESAs.
How this was made
The 30-second read
Why it matters
The earnings miss and pricing concerns may trigger short‑term sell pressure, but the pipeline data and cash position provide a floor for longer‑term investors.
Market read
Earnings and trial data are material for AKBA shareholders and biotech investors; limited spillover to broader markets.
What to watch
Potential upside from upcoming Phase 2 data on praliciguat and ebribafusp, and cash runway of $159M.
Background
Akebia Therapeutics (NASDAQ:AKBA) focuses on anemia treatments for chronic kidney disease. The Q3 call covered financial results, trial outcomes, and contract negotiations with major dialysis providers.
Ticker impact
Akebia Therapeutics reported Q3 revenue of $36.9M, a net loss of $14.4M and disclosed trial results for Vafseo, plus contract updates with DaVita and Fresenius.
likely downward pressure as investors digest lower revenue and net loss
Revenue fell 37% YoY, net loss widened, and guidance indicates continued pricing pressure, which typically depresses share price in the near term.
Market effects
Kidney‑disease therapeutics sector may see heightened scrutiny on pricing and reimbursement trends.
U.S. biotech investors may reassess exposure to small‑cap anemia drugs.
Limited to niche biotech investors; no broad market impact.
Counterpoint
If Vafseo gains market share despite pricing pressure, the stock could rebound on long‑term upside.
Key entities
- CompanyAkebia Therapeutics
Biopharma developing Vafseo and pipeline candidates.
- PartnerDaVita
Dialysis provider negotiating Vafseo contracts.
- PartnerFresenius
Potential future Vafseo customer.
